Zelenectide pevedotin shows a 45% ORR in metastatic urothelial cancer (mUC) with an 11.1-month median duration of response and a favorable safety profile.
Roche's Genentech unit partners with Bicycle Therapeutics in a $1.7 billion deal to leverage innovative bicyclic peptide platform for cancer immunotherapy development, with a $30 million upfront payment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.